Mechanisms and consequences of dysregulation of the Tiam family of Rac activators in disease.


Journal

Biochemical Society transactions
ISSN: 1470-8752
Titre abrégé: Biochem Soc Trans
Pays: England
ID NLM: 7506897

Informations de publication

Date de publication:
18 12 2020
Historique:
received: 01 09 2020
revised: 16 10 2020
accepted: 16 10 2020
pubmed: 18 11 2020
medline: 10 8 2021
entrez: 17 11 2020
Statut: ppublish

Résumé

The Tiam family proteins - Tiam1 and Tiam2/STEF - are Rac1-specific Guanine Nucleotide Exchange Factors (GEFs) with important functions in epithelial, neuronal, immune and other cell types. Tiam GEFs regulate cellular migration, proliferation and survival, mainly through activating and directing Rac1 signalling. Dysregulation of the Tiam GEFs is significantly associated with human diseases including cancer, immunological and neurological disorders. Uncovering the mechanisms and consequences of dysregulation is therefore imperative to improving the diagnosis and treatment of diseases. Here we compare and contrast the subcellular localisation and function of Tiam1 and Tiam2/STEF, and review the evidence for their dysregulation in disease.

Identifiants

pubmed: 33200195
pii: 226971
doi: 10.1042/BST20200481
doi:

Substances chimiques

Guanine Nucleotide Exchange Factors 0
T-Lymphoma Invasion and Metastasis-inducing Protein 1 0
TIAM1 protein, human 0
TIAM2 protein, human 0
rac GTP-Binding Proteins EC 3.6.5.2
rac1 GTP-Binding Protein EC 3.6.5.2

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

2703-2719

Subventions

Organisme : Cancer Research UK
ID : C5759/A20410
Pays : United Kingdom

Informations de copyright

© 2020 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society.

Auteurs

Joe Maltas (J)

Cell Signalling Group, Cancer Research UK Manchester Institute, The University of Manchester, Alderley Park SK10 4TG, U.K.

Hannah Reed (H)

Cell Signalling Group, Cancer Research UK Manchester Institute, The University of Manchester, Alderley Park SK10 4TG, U.K.

Andrew Porter (A)

Cell Signalling Group, Cancer Research UK Manchester Institute, The University of Manchester, Alderley Park SK10 4TG, U.K.

Angeliki Malliri (A)

Cell Signalling Group, Cancer Research UK Manchester Institute, The University of Manchester, Alderley Park SK10 4TG, U.K.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH